One of India’s leading pharmaceutical companies, Sanjivani Parenteral Limited, has shown tremendous growth in the stock market in one year. The shares which closed at Rs 198 on Monday, achieved their new 52-week high, that is Rs 203, today on April 23. In one year, this multi-bagger stock has given a return of 274 percent to its investors. Veteran investor Ashish Kacholia has also invested in this stock in the March quarter. According to the company’s shareholding data, Ashish Kacholia holds 3.70 lakh equity shares or a 3.2 percent stake in Sanjivani Parenteral Limited. The total value of investment in his company is around Rs 7.5 crore. This move must not have surprised the market experts, as this multi-bagger stock has given over 1,718 percent return to its investors in three years. In the last month, the returns have been recorded at 30.46 percent. The market capitalisation of this stock currently stands at Rs 233 crore.
After the huge investment, the latest shareholding pattern of the company has seen a dip in the holding by the promoters from 32.4 percent to 27.67 per cent in the third quarter of 2023. The public shareholders hold a 62.6 percent stake in the company. The institutional investors holding has increased from 6.01 percent to 9.71 percent in this quarter.
One year ago, the price of this share was around Rs 50.54, which has now become Rs 203. The price of this stock has increased by more than 21 percent in the last two trading sessions alone. In the last six months, Sanjivani Parenteral shares have given 41 percent returns to investors.
According to Trendlyne.com, Ashish Kacholia holds 50 stocks with a net worth of more than Rs 3,090.4 crore. Safari Industries, Universal Autofoundry, Balu Forge Industries, Raghav Productivity Enhancer and Shaily Engineering Plastics are some of the major stocks in his portfolio. He is also called a Big Whale of the stock market by the media. Ashish Kacholia founded Lucky Securities Brokerage firm in 1995.
Disclaimer: The copyright of this article belongs to the original author. Reposting this article is solely for the purpose of information dissemination and does not constitute any investment advice. If there is any infringement, please contact us immediately. We will make corrections or deletions as necessary. Thank you.
